← All trials
NCT05184569
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2022
- Primary completion
- Jun 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Jan 11, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institute on Aging (NIA)Collaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
- Alzheimer's AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.